29 results about "Human placenta" patented technology

An acellular product may be derived from human placenta and may be used in various scenarios for wound healing. Because the product may be acellular, the product may be processed for storage and transportation with minimal degradation. The product may include various scaffolding such as biomaterials or human tissue, and the scaffolding may be infused with various plasmas and agents. The cell-free treatment may maintain the biological activity of many therapeutic agents found within cells and may possess multiple structural components to support cellular attachment. The structural components or scaffolds may function as a reservoir of highly diffusible chemotactic and cellular-programming factors that may be useful to treat injury and disease.

One or more techniques and / or systems are disclosed for formulating a skin care product to mitigate aging or to restore damaged skin. One skin care product includes a blend of growth factors, peptides, and amino acids. Also disclosed is a skin care product formed from a synthesized protein matrix. The synthesized protein matrix can mimic the regenerative effects of human placental proteins, which are desirable when applied to skin because, as skin loses its regenerative properties, humans shows signs of aging, and a decrease in healing capabilities. The exemplary skin-care products disclosed herein can be applied to skin to help mitigate this skin aging process or to restore damaged skin.

The invention discloses a traditional Chinese medicine composition for treating sepsis as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from 1-15 parts of sulfur, 3-25 parts of calamitas urinae hominis, 1-20 parts of wine-treated rhubarb, 10-30 parts of fructus cannabis, 10-50 parts of radix bupleuri, 5-30 parts of scutellaria baicalensis, 5-25 parts of folium isatidis, 5-25 parts of peach kernels, 5-30 parts of salvia miltiorrhiza, 5-30 parts of angelica sinensis, 5-30 parts of sophora flower charcoal, 5-25 parts of fructus gardeniae praeparatus and 5-60 parts of wine-treated fructus corni. According to the invention, through a combined mode of'monarch drug targeted oral administration and synergistic decoction of minister, assistant and guide drugs', the whole-course intervention of'upstream inhibition, midstream blocking and downstream regulation 'on sepsis immune disorder can be realized, meanwhile, the functions of warming yang, dispelling cold, cooling blood and detoxifying are taken into account, and the pro-inflammatory / anti-inflammatory balance is successfully recovered to a physiological state; the action mode is superior to that of a traditional single anti-inflammatory strategy and a traditional Chinese medicine application mode of whole-prescription decoction. In a standard animal model, the traditional Chinese medicine composition definitely shows the dose-dependent extremely remarkable effects of anti-inflammation, immunoregulation, multi-organ protection and overall condition improvement, the curative effect of a high-dose group of the traditional Chinese medicine composition is equivalent to that of a classic potent medicine, and the traditional Chinese medicine composition has more advantages in the aspects of recovering immune homeostasis, warming yang and strengthening the body resistance.

Provided according to one aspect of the present disclosure is a composition for wound healing or tissue regeneration that comprises a genomic DNA fragment extracted from human placenta-derived mesenchymal stem cells and a placental growth factor and which exhibits excellent tissue regeneration ability. Provided according to another aspect of the present disclosure is a preparation method which enables the efficient, biocompatible, economical, and environmentally friendly production of a composition for wound healing or tissue regeneration having excellent tissue regeneration ability.

The invention relates to construction of a proline hydroxylase alpha subunit mutant from a human placenta and an expression vector of the proline hydroxylase alpha subunit mutant, and a mutant protein which is efficiently expressed in Ecoli BL21 (DE3) and has greatly improved hydroxylation efficiency and a construction body of the mutant protein are obtained by analyzing and screening a natural hydroxylase subunit.

The present invention relates to a microfluidic device configured to study epithelial and / or endothelial barrier function in a human 3D cell microtissue model, while simultaneously allowing for the application of mechanical stimuli such as luminal flow and / or lateral flow. Embodiments include three cultures representing the maternal-fetal interface (placental barrier): human umbilical vein endothelial cells (HUVEC), human placental fibroblasts (HPF), and human placental pericytes (HPP), as well as a ductal interface composed of human primary mammary gland-derived endothelial cells, fibroblasts, and epithelial layer (MCF10). The model is expandable to include tumors (cell line-derived or patient-derived). The present invention further relates to a method for fabricating a human 3D vascular microtissue model using a microfluidic device according to the present invention, and to the use of a human 3D vascular microtissue model for, for example, studying the effects of cell barrier function (solute permeability), interstitial flow, luminal flow and / or lateral flow, and epithelial and / or endothelial barrier function (solute permeability), and extravascular matrix properties (diffusivity, stiffness, transport of molecules, antibodies and / or cells, and matrix proteins). The present invention further relates to a method for presenting a pre-eclampsia (disease) model of the placental barrier, and means for testing drug therapies.

The invention relates to the technical field of immune cells, in particular to a preparation method of human placenta-derived NK cells. The preparation method comprises the following steps: S1, separating placenta tissues; s2, placenta tissue digestion; S3, mononuclear cell separation; S4, NK cell sorting; and 5, NK cell multiplication culture.

The invention discloses a human placenta-derived endothelial progenitor cell and a combined drug thereof as well as application of the human placenta-derived endothelial progenitor cell in preparation of a drug for treating radiation-induced thymus injury, and discloses a novel cell treatment drug for reconstructing a thymus microenvironment, recovering T cell generation and promoting thymus function repair and immune reconstruction aiming at thymus radiation injury. The placenta-derived endothelial progenitor cells are found to have an excellent effect of treating the radiation thymus injury, and the human placenta-derived endothelial progenitor cells and the human umbilical cord mesenchymal stem cells are synergistically combined to have a synergistic effect on treating the radiation thymus injury.

The invention discloses a human placenta organoid gene intervention method based on lentivirus transfection, and belongs to the technical field of biological medicine. According to the method, key parameters of lentivirus transfection, namely the volume ratio of cell suspension to lentivirus to DMEM (Dulbecco Modified Eagle Medium) of 10: 2: 40 and the optimal transfection time of 4 hours, are optimized and determined, so that high transfection efficiency is ensured, the adverse effect of the virus on the activity of the organoid is remarkably reduced, and good organoid balling capacity and normal growth state are maintained. According to the invention, stable and controllable gene intervention is realized in a three-dimensional organoid model which highly simulates the structure and function of a human placenta for the first time, and the obtained placenta organoid subjected to gene intervention has a great significance for deeply researching the molecular mechanism of placenta development in a highly bionic in-vitro environment and exploring the pathogenesis of pregnancy-related diseases such as preeclampsia and the like. And an ideal research platform which is reliable and close to the physiological state is provided by screening or evaluating intrauterine gene therapy strategies.

The invention belongs to the technical field of biology, and particularly relates to separation and application of proteasome-rich human placenta-derived vascular stem cell outer vesicles. The extracellular vesicles provided by the invention are derived from human placenta source blood vessel promoting stem cells, and the human placenta source blood vessel promoting stem cells show that markers PAI-1 are positive, MECOM is positive, CD201 is positive, CD44 is positive, CD73 is positive, HLA-ABC is positive, CD34 is negative, CD31 is negative and CD326 is negative. Compared with human umbilical cord mesenchymal stem cell outer vesicles, the human placenta-derived vascular stem cell outer vesicles provided by the invention are rich in proteasomes and angiogenic protein factors, wherein the proteasomes have high chymotrypsin-like activity. Moreover, in-vivo and in-vitro experimental data show that the human placenta-derived vascular stem cell outer vesicles provided by the invention are rich in proteasomes, and can degrade accumulation of HIF and inhibit cell apoptosis; the medicine has a treatment effect on myocardial infarction.

The invention discloses a preparation method of traditional Chinese medicine composition gecko pills for treating lung diseases, and relates to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine composition gecko pills comprise 20 parts of abelmoschus manihot, 12 parts of gecko, 12 parts of human placenta, 12 parts of ginseng, 10 parts of fritillaria, 10 parts of almond, 10 parts of lily, 10 parts of rhizoma polygonati, 10 parts of medlar, 10 parts of cistanche, 10 parts of astragalus membranaceus, 10 parts of cynomorium songaricum, 10 parts of fried malt and 10 parts of endothelium corneum gigeriae galli. Abelmoschus manihot, fritillaria, almond, lily, polygonatum kingianum, medlar, cistanche, astragalus membranaceus, cynomorium songaricum, fried malt and endothelium corneum gigeriae galli are cleaned and then dried at the low temperature of 55 DEG C until the water content is lower than 7%. The gecko and the human placenta are used as monarch drugs to tonify the lung and the kidney, absorb qi and relieve asthma; the ginseng and the astragalus membranaceus tonify qi and strengthen superficies, and the fritillaria and the almonds reduce phlegm and The abelmoschus manihot, the rhizoma polygonati and the Chinese wolfberry have the effects of nourishing yin and moistening lung; roasted malt and endothelium corneum gigeriae galli are used for strengthening spleen and stomach, and preventing greasy Effective components with different polarities are fully extracted by a three-stage countercurrent extraction process; and the bioavailability of the animal medicinal materials is improved by a superfine grinding technology.

The invention relates to the technical field of biological medicine, in particular to an autophagosome for promoting hair growth and an extraction method and application thereof. Comprising the following steps: inoculating human umbilical vein endothelial cells or human placenta mesenchymal cells into a DMEM (Dulbecco Modified Eagle Medium) complete medium, and culturing until the cell fusion degree reaches 80-90%; replacing the DMEM complete culture medium with a serum-free DMEM culture medium, collecting supernate after culture is completed, and centrifuging the supernate to obtain a crude extract containing the autophagosome; and resuspending the crude extract by using PBS, adding an LC3 antibody, and finely extracting by using a paramagnetic particle method to obtain the autophagosome. The method has the advantages of simple operation process, no need of other inducers in the process of inducing the formation of the autophagosome, no too high requirements on laboratories, and high yield of the autophagosome, and provides an efficient, convenient, economical and practical treatment means for alopecia patients.

The invention relates to the technical field of stem cells, in particular to a preparation method of human placenta amnion pluripotent stem cells. The method specifically comprises the following steps: S1, tissue pretreatment and physical pre-layering; s2, carrying out mechanical-enzymatic synergistic dynamic dissociation; s3, gradient purification and washing; s4, performing soft matrix phenotype maintenance culture; according to the method disclosed by the invention, the separation efficiency of amniotic epithelial cells is improved and the enzyme exposure load is reduced through synergistic enzymolysis of Dispase II and Trypsin in combination with weak shearing force generated by the magnetic beads. Meanwhile, SB431542 blocks a signal channel to prevent EMT, a GelMA soft matrix maintains cell phenotypes, and Percoll density gradient centrifugation is matched to improve cell purity.

The invention provides a composition for treating male erectile dysfunction by combining human prepuce mesenchymal stem cell exosome with human placenta mesenchymal stem cells and application, and relates to the technical field of biological medicine. The composition comprises human prepuce mesenchymal stem cell exosome particles and human placenta mesenchymal stem cells. The human prepuce mesenchymal stem cell exosome particles and the human placenta mesenchymal stem cells are core components and have the repairing effects of revascularization, nerve repairing, fibrosis resistance and the like. The composition also comprises glutathione, L-arginine, icariin, ginseng stem and leaf total saponins, mecobalamin and human serum albumin, can provide functional support and antioxidant protection, ensures the instant effect, and creates an environment for restoration. According to the invention, multi-target and fundamental treatment of male erectile dysfunction is realized through an action mode of quick effect taking, synergistic repair and long-acting reconstruction, and symptoms of male erectile dysfunction are remarkably improved.

The invention belongs to the technical field of biomedicine, and relates to a culture medium for human placenta organoid in early pregnancy as well as preparation and application of the culture medium. The culture medium is prepared from DMEM / F12, and an N-2 additive is added into the culture medium; a B-27 additive; primary cell antibiotics; and N, N-acetyl-L-cysteine; l, L-glutamine; recombinant human epidermal growth factors; cHIR99021, CHIR99021; a recombinant human R-spinal protein 1; recombining a human fibroblast growth factor; recombinant human hepatocyte growth factors; a83-01, A83-01; prostaglandin E2; y-27632, Y-27632; and fetal bovine serum albumin. By improving the components of the culture medium of the human placenta organoid, the obtained human placenta organoid is better in growth state and balling rate, the apoptosis of the organoid is reduced, and a foundation is laid for further application to research of downstream molecular biology and cytobiology.

The invention discloses a stably produced mesenchymal stromal cell exosome containing anti-inflammatory miRNA effective components and a preparation method and application of the mesenchymal stromal cell exosome. The preparation method comprises the following steps: S1, obtaining placenta tissues, and performing isolated culture on primary placenta mesenchymal stromal cells; s2, constructing an immortalized placenta mesenchymal matrix cell line through a lentivirus transduction hTERT gene; s3, culturing the immortalized placenta mesenchymal matrix cell line in a serum-free culture medium, and collecting a cell supernatant; s4, the obtained supernate is sequentially subjected to centrifugation, PEG precipitation and ultrafiltration concentration, and exosome is extracted. According to the invention, hTERT immortalized human placenta mesenchymal stromal cells (iMSC022) of a single donor are adopted as a production source of the exosome (Exo), so that the application limitation of traditional primary cells is remarkably broken through. Compared with a mode that a primary mesenchymal stromal cell (MSC) needs to depend on multi-donor mixing to construct a cell bank due to limited multiplication capacity, the iMSC022 has high homogeneity after lentiviral transfection and resistance screening.

One or more techniques and / or systems are disclosed for formulating a skin care product to mitigate aging or to restore damaged skin. One skin care product includes a blend of growth factors, peptides, and amino acids. Also disclosed is a skin care product formed from a synthesized protein matrix. The synthesized protein matrix can mimic the regenerative effects of human placental proteins, which are desirable when applied to skin because, as skin loses its regenerative properties, humans shows signs of aging, and a decrease in healing capabilities. The exemplary skin-care products disclosed herein can be applied to skin to help mitigate this skin aging process or to restore damaged skin.

The invention discloses a placenta injection ovary local puncture preparation under B ultrasound guidance and a preparation method of the placenta injection ovary local puncture preparation, and relates to the technical field of gynecological interventional diagnosis and treatment, and the placenta injection ovary local puncture preparation comprises the following components by weight: 30-80 parts of placenta extract; 5-20 parts of a stabilizer; 20-50 parts of an osmotic pressure regulator; 1-5 parts of a pH regulator; 0.5 to 2 parts of an antioxidant; and the balance of water for injection. The placenta extract is a mixed active component which is obtained after healthy human placenta is subjected to low-temperature enzymolysis and centrifugal purification and contains polypeptide, growth factors and nucleic acid, the content of the polypeptide is not lower than 1.2 mg / mL, and the content of epidermal growth factors is not lower than 50 pg / mL. The problems of unstable activity and poor local compatibility of a traditional preparation are solved, stimulation is reduced, and the storage period is prolonged; all links are optimized through a whole-process innovative preparation process, active ingredients are reserved to the maximum extent, pollution risks are reduced, batch-to-batch differences are reduced, and the preparation quality is guaranteed.

The invention belongs to the technical field of biomedicine, and relates to a culture method of human placenta organoid in early pregnancy. The method comprises the following steps: collecting placenta villus for 6-10 weeks, digesting, filtering and centrifuging to obtain a mixture of placenta villus cells and blood cells; splitting the red blood cells, and centrifuging to obtain placenta villus cells; counting placenta villus cells, adding an organoid culture medium (2), re-suspending the cells, and mixing the cells and matrigel according to a ratio of 1: 3 to prepare drops; placing the culture plate upside down at 37 DEG C, culturing for 2-5 minutes, placing the culture plate upside down, continuously placing for 5-10 minutes, and adding an organoid culture medium (2) for culturing to obtain the placenta organoid. By improving the culture method of the placenta organoid, the obtained placenta organoid is higher in balling rate, the culture distribution of the placenta organoid is more uniform, and the placenta organoid culture method can be further applied to various downstream molecular biology and cytobiology researches.

The present application relates to a microfluidic device configured to study epithelial and / or endothelial barrier function in a human 3D cell micro-tissue model while making it possible to apply a mechanical stimulus such as luminal flow and / or lateral flow. Embodiments include a ternary culture of human umbilical vein endothelial cells (HUVEC), human placental fibroblasts (HPF), and human periplacental cells (HPP) representing the maternal-fetal interface (placental barrier), and a mammary duct interface comprising primary human mammary gland-derived endothelial cells, fibroblasts, and comprising an epithelial layer (MCF10). The model can be expanded to contain (cell line-derived or patient-derived) tumors. The invention also relates to a method for preparing the human 3D blood vessel micro-tissue model by using the microfluidic device, and application of the human 3D blood vessel micro-tissue model in research on cell barrier function (solute permeability), influence of interstitial substance, lumen and / or lateral flow, and the like. And uses in studying epithelial and / or endothelial barrier function (solute permeability) and extravascular matrix properties (diffusivity, stiffness, transport of molecules, antibodies and / or cells, and matrix proteins). The present application also relates to methods for constructing a model of preeclampsia (disease) of the placental barrier, as well as methods for testing drug therapy.

The application provides application of a YTHDC1 inhibitor in preparation of a medicine for preventing and treating premature birth, and the medicine takes YTHDC1 gene as a target for placental trophoblasts. The application is based on the fact that the expression level of human YTHDC1 gene in premature placental tissue is significantly higher than that in full-term placenta, a stable overexpression cell strain is constructed aiming at human YTHDC1 gene, and specific siRNA is designed to specifically increase or reduce YTHDC1 expression in human placental trophoblasts, which can correspondingly promote or inhibit the proliferation, apoptosis, migration and invasion ability of the cells. Meanwhile, by injecting in vivo biological preparations interfering with the expression of YTHDC1 gene in an animal model, the expression of YTHDC1 at the placental site can be reduced, the delivery time is prolonged, and the purpose of delaying the occurrence of premature birth is achieved. The application provides a possibility for the development of a clinical premature birth treatment medicine based on YTHDC1 gene, and has great application value and prospect.

The application provides a rat uterine perfusion model and a construction method and application thereof, and belongs to the technical field of animal models. The construction method comprises the following steps: ligating blood vessels at a left kidney of a dead pregnant rat, blood vessels at a bifurcation of the upper end of the left kidney, bifurcation of the upper side and both sides of the internal iliac artery and the internal iliac vein, the right kidney and the bifurcation of the abdominal aorta and the posterior vena cava, and then inserting a tube into the abdominal aorta and the posterior vena cava, and pumping perfusion liquid from the abdominal aorta to obtain the model. The model forms a reproductive artery-placenta-fetus-placenta-reproductive vein circulation, maximally guarantees placental activity, and retains complete placental tissue. The model is simple to prepare and easy to obtain, can more truly and accurately simulate the circulation process of maternal body temperature and complete nutrients in the placenta supplied to the fetus through the mother and the placenta in the whole permeability experiment, and thus more objectively studies the permeability of a compound in the placenta, and is more reliable than a human placental perfusion model.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

The invention belongs to the technical field of probiotics and traditional Chinese medicines, and mainly relates to a complex microbial inoculant for fermenting traditional Chinese medicines, which comprises saccharomyces cerevisiae CICC-1445 and saliva combined lactobacillus CICC-23179. The invention relates to a traditional Chinese medicine composition and a preparation process thereof, in particular to a traditional Chinese medicine composition with the effects of promoting blood circulation to remove blood stasis and improving thrombus, cerebral ischemia and impotence and a preparation process thereof. According to the formula, the traditional Chinese medicine composition comprises gizzard pepsin, myrobalan meat, salvia miltiorrhiza, angelica sinensis, agilawood, fermented soybean, ligusticum wallichii, leonurus, folium ginkgo, gastrodia elata, radix puerariae, raspberry, semen cuscutae, cynomorium songaricum, morinda officinalis, eucommia ulmoides, hairyvein agrimony, beautiful millettia root, semen allii tuberosi, amber, red ginseng, pseudo-ginseng, musk, scorpio, centipede, leech, dragon's blood, saffron crocus, lumbricus, benzoin, paris polyphylla, human placenta, cowherb seed, cornu cervi pantotrichum and herba epimedii. The prepared composition has the effects of promoting blood circulation to remove blood stasis and improving thrombus, cerebral ischemia and impotence.

The application relates to a determination method of volatile components in human dan, wherein the human dan comprises a core and a coating wrapped on the core; the material of the core comprises menthol, cassia, liquorice, catechu, costus, borneol, platycodon, camphor, cumin, cardamom and clove basil oil; the material of the coating is a non-aluminum water-soluble material; the determination method comprises the following steps: taking a human dan sample to be determined, adding an organic solvent and water to extract, and preparing a test sample solution; taking standard samples of menthol, borneol and camphor, adding a solvent to dissolve, and preparing a reference solution; taking the test sample solution and the reference solution, and performing gas chromatography analysis, and determining by using an external standard method. The determination method has the advantages of few interfering substances in the test sample solution, complete effective components, simplicity, feasibility, accuracy, rapidness and good stability.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

The invention discloses a human placenta organoid gene intervention method based on adeno-associated virus transfection, and belongs to the technical field of biomedicine. The method comprises the following steps: firstly, collecting early pregnancy placenta villus cells and constructing primary human placenta organoid; after being digested into single cells, the single cells are mixed with adeno-associated viruses capable of intervening in target genes for transfection; different serotypes of AAV-2, 5, 6, 8, 9 and DJ adeno-associated viruses are screened, the mixing volume ratio of a single-cell suspension of a primary placenta organ to the adeno-associated viruses is 5: 1, 10: 1 and 20: 1, and the transfection time is 5-20 min. According to the method, the AAV-DJ is determined to be an efficient serotype through screening, key parameters that the volume ratio of cells to viruses is 5: 1 and transfection is conducted for 10 min are optimized, and the organoid activity is maintained while high transfection efficiency is guaranteed. The invention provides a reliable platform for researching a placenta development mechanism and intrauterine gene therapy.

Provided herein are new and useful placental derived natural killer (NK) Cell or population thereof, or one or more cells within the population that express a cleavage resistant CD 16 polypeptide and a secreted IL-15 polypeptide, as well as uses thereof.